jp morgan h&q healthcare conference january 7 2003 shire pharmaceuticals group plc comment on the safe harbor statement under private securities litigation reform act of 1995 statements made during today s presentation or in response to questions question & answer period that are not historical facts forward looking such involve a number risks and uncertainties subject change at any time event materialise results could be materially affected include but limited associated with inherent uncertainty pharmaceutical research product development commercialisation impact competitive products including same adhd franchise patents government regulation approval expected date lanthanum carbonate fosrenol fosnol other detailed from periodic reports produced by annual report filed form 10k exchange commission trademark information unless otherwise indicated certain names set out this document trademarks
